Seven Fleet Capital Management LP Invests $1.16 Million in Larimar Therapeutics, Inc. $LRMR

Posted by on Aug 2nd, 2026

Seven Fleet Capital Management LP bought a new position in Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 256,585 shares of the company’s stock, valued at approximately $1,155,000. Seven Fleet Capital Management LP owned approximately 0.25% of Larimar Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its position in Larimar Therapeutics by 75.8% in the third quarter. BNP Paribas Financial Markets now owns 10,146 shares of the company’s stock worth $33,000 after buying an additional 4,376 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Larimar Therapeutics during the 4th quarter worth $60,000. Sei Investments Co. boosted its stake in shares of Larimar Therapeutics by 54.5% during the 1st quarter. Sei Investments Co. now owns 16,336 shares of the company’s stock worth $74,000 after acquiring an additional 5,763 shares in the last quarter. Coldstream Capital Management Inc. acquired a new position in shares of Larimar Therapeutics in the 3rd quarter worth $57,000. Finally, Strs Ohio grew its holdings in shares of Larimar Therapeutics by 174.7% in the 1st quarter. Strs Ohio now owns 21,700 shares of the company’s stock worth $98,000 after acquiring an additional 13,800 shares during the last quarter. 91.92% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Larimar Therapeutics news, Director Thomas Edward Hamilton bought 50,000 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were bought at an average price of $3.34 per share, for a total transaction of $167,000.00. Following the acquisition, the director directly owned 714,798 shares of the company’s stock, valued at approximately $2,387,425.32. This trade represents a 7.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

LRMR has been the subject of several analyst reports. Citigroup reaffirmed a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday, June 30th. Wall Street Zen upgraded Larimar Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Robert W. Baird reduced their price objective on shares of Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a research note on Tuesday, June 30th. Wedbush decreased their target price on shares of Larimar Therapeutics from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Monday, May 18th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Larimar Therapeutics in a research report on Wednesday, May 27th. They issued an “overweight” rating and a $9.00 target price on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Larimar Therapeutics has a consensus rating of “Buy” and a consensus target price of $12.71.

Read Our Latest Research Report on LRMR

Larimar Therapeutics Stock Down 0.3%

Shares of Larimar Therapeutics stock opened at $3.82 on Friday. Larimar Therapeutics, Inc. has a 12 month low of $2.71 and a 12 month high of $6.42. The stock has a market cap of $396.82 million, a PE ratio of -1.85 and a beta of 0.83. The business has a fifty day simple moving average of $3.58 and a 200-day simple moving average of $3.95.

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.22. Analysts expect that Larimar Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Larimar Therapeutics Profile

(Free Report)

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.

Featured Stories

Institutional Ownership by Quarter for Larimar Therapeutics (NASDAQ:LRMR)

Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.